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Price, O. J.; Ansley, L.; Levai, I.; Molphy, J.; Cullinan, P.; DIckinson, J. W.; Hull, J. H. 
 
Response to Professor Mastronarde:  
Eucapnic voluntary hyperpnea testing in asymptomatic athletes  
 
We appreciate Professor Mastronarde’s interest and comments concerning our cross-sectional analysis 
of eucapnic voluntary hyperpnea (EVH) testing in a cohort of elite and sub-elite asymptomatic 
athletes (1). We agree that self-report respiratory symptoms (e.g. wheeze, dyspnea, and cough) 
provide limited value when confirming or refuting a diagnosis of exercise-induced 
bronchoconstriction (EIB) or asthma in athletes. Indeed we have recently published both quantitative 
(2) and qualitative data in support of this concept (3). Moreover, there is currently no ‘gold standard’ 
objective test to diagnose EIB in athletes (4); thus classifying athletes as ‘healthy’ from a respiratory 
point of view, is a significant challenge.  
Our analysis excluded athletes with a prior objective diagnosis of airways disease and/or those 
prescribed asthma medication (1). However, as Professor Mastronarde (5) quite rightly highlights, we 
did not perform comprehensive airway inflammatory profiling and this is an important study 
limitation. Future work should focus on addressing this deficiency, and as previously mentioned, a 
comparison between EVH and commensurate exercise challenge airway response (ventilation 
matched) is certainly an important research priority.  
Regardless, it is important to recall that many of the original diagnostic cut-off values for surrogate 
bronchoprovocation challenges used in the diagnosis of EIB in athletes have been established based 
largely on data derived from non-athletic cohorts +/- prior diagnosis of asthma +/- perceived 
symptoms +/- previously treated. In our previous study, where we screened British-based elite athletes 
using EVH, the mean fall in EIB-negative athletes was −4.6 ± 2.9% (n = 150) (6). The normal 
response to an EVH challenge in elite athletes therefore appears to be a small reduction in FEV1 when 
compared with baseline measurements. However, using a population, who report no symptoms and 
have no prior history of EIB allows us to investigate an abnormal threshold (1).  
It is important to highlight that if we limit our population to those that have a maximum fall in FEV1 
post EVH <10% (i.e. EVH negative athletes based on current guidance) the threshold at which we 
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suggest an abnormal response is set at 10%. To put this into context, if we re-analyse the dataset from 
our study, and exclude any athlete with ≥10% fall in FEV1 post EVH, based on the remaining athletes 
(n = 134), the mean fall in FEV1 would be calculated as -4.9 ± 2.6%. However, this approach is 
artificially impacting the upper limit of a normal response. It is therefore only appropriate, when re-
evaluating a diagnostic threshold, to analyse and interpret data from the entire cohort (n = 224), rather 
than classifying athletes as having a normal or abnormal airway response based on existing criteria 
(4). 
Overall, we thank Professor Mastronarde (5) for highlighting important deficiencies in our current 
work and concede our approach may have overlooked the potential inclusion of asymptomatic 
athletes who had mild forms of undetected airway dysfunction and/or active airway inflammation. 
Irrespective of these limitations, we consider the data provided in a population of highly-trained 
athletes to add to the evidence-base in the field. Further research should be conducted prior to 
modifying the American Thoracic Society (ATS) clinical practice guideline statement (4).  
 
Oliver J. Price1 PhD - on behalf of all co-authors.  
Les Ansley4 PhD  
Irisz Levai5 MD 
John Molphy6 PhD 
Paul Cullinan2 PhD 
John W. Dickinson5PhD  
James H. Hull2,3 FRCP, PhD 
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Note:  
- Our original letter has been incorrectly cited as Hull et al. rather than Price et al.  
- The prevalence estimates provide by Professor Mastronarde are incorrect:  
 
5. Parsons JP, Cosmar D, Phillips G, Kaeding C, Best TM, Mastronarde JG. Screening for 
exercise-induced bronchoconstriction in college athletes. J Asthma 2012 Mar; 49 (2):153-7. 
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